300841.SZ
康华生物
SZSE · Healthcare · C 制造业 · CN
CNY 53.27
−5.72%Year over year
Reported trailing growth
- Revenue
- -4.7%
- EBITDA
- —
- EBIT
- -14.5%
- EPS
- -14.4%
- Free cash flow
- +10.1%
- Operating cash flow
- -8.7%
Forward estimates
Based on analyst estimates
- Revenue
- -69.6%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.0%
- EBITDA
- -21.7%
- EBIT
- -27.6%
- Net income
- -28.4%
- EPS
- -27.6%
- Free cash flow
- -13.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026